BioSpace News Archive

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) and IASO Biotechnology (“IASO Bio”) today jointly announced that the updated data from Phase 1b/2 study of Equecabtagene Autoleucel (Innovent R&D code: IBI326, IASO Bio R&D code: CT103A) was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2-6, 2023.

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628) has presented updated data of Cohort C from a phase I/IIa, multi-center study of Osemitamab (TST001) in combination with Capecitabine and Oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Telix Pharmaceuticals Limited advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Conference being held in New York from June 7 to June 9, 2023.

Ascentage Pharma announced that it has released preliminary results from a Phase Ib/II study of the Bcl-2 inhibitor, lisaftoclax, as a monotherapy or combined with ibrutinib or rituximab in patients with Waldenström macroglobulinemia, in a Poster Presentation at the 59th American Society of Clinical Oncology Annual Meeting that marked the first data readout from a multicenter global study of lisaftoclax in WM.